Provided By GlobeNewswire
Last update: Nov 20, 2024
Nes-Ziona, Israel, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Company’s Board of Directors approved the purchase of up to $1 million of Bitcoin as part of its cash management strategy.
Read more at globenewswire.comNASDAQ:ENLV (6/20/2025, 8:00:02 PM)
1.09
+0.05 (+4.31%)
Find more stocks in the Stock Screener